EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Omalizumab treatment in combination with any other biologics: Is it really a safe duo?

Sema Koç Yıldırım iD, Ece Erbağcı iD, Aslı Hapa

Australasian Journal of Dermatology · 2023

DOI: 10.1111/ajd.14019 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Australasian Journal of Dermatology, 2023. Verfasst von Sema Koç Yıldırım und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Uşak University Faculty of Medicine, Uşak, Turkey. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Urticaria, Chronic Urticaria, Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic spontaneous urticaria (CSU) is a mast cell‐mediated disease, which is sometimes associated with various inflammatory disorders. Omalizumab is a commonly used biological agent, which is a recombinant, humanized, monoclonal antibody against human immunoglobulin E. However, there are only few reports about the combination of omalizumab for CSU with any other biologics for accompanying inflammatory diseases in the literature. The aim of this study was to evaluate the patients whose treatment of omalizumab for CSU were combined with any other biologics for associated inflammatory disorders and to describe whether these combinations might have any safety concerns.

Methods

We conducted a retrospective cohort study of adult patients with CSU treated with omalizumab concurrently using another biological agent for their other dermatological conditions.

Results

Thirty‐one patients, 19 women and 12 men, were evaluated. The mean age was 45.13 years. The median duration of omalizumab was 11 months. Biological agents which patients were treated other than omalizumab were as follows: adalimumab biosimilar ( n = 3), ustekinumab ( n = 4), secukinumab ( n = 17) and ixekizumab ( n = 7). The median duration of concurrent use of omalizumab and other biologics was 8 months. None of the drug combinations was stopped because of side effects.

Conclusion

This observational study demonstrated that omalizumab treatment for CSU in combination with any other biological agents for dermatological disorders appeared to be well tolerated without any major safety concerns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Allergic AgentsUrticariaChronic UrticariaBiosimilar PharmaceuticalsAdultMaleHumansFemaleMiddle AgedOmalizumabRetrospective StudiesTreatment OutcomeChronic DiseaseBiological Factors

Stichwörter der Autor:innen

biologicalchronic spontaneous urticariaomalizumabtreatment

Substanzen

OmalizumabAnti-Allergic AgentsBiosimilar PharmaceuticalsBiological Factors

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, Uşak University Faculty of Medicine, Uşak, Turkey.
  • Department of Dermatology and Venereology, Buca Seyfi Demirsoy Training and Research Hospital, İzmir, Turkey.

ORCID-Profile: Sema Koç Yıldırım, Ece Erbağcı

Zitieren

APA

Koç Yıldırım, S., Erbağcı, E., & Hapa, A. (2023). Omalizumab treatment in combination with any other biologics: Is it really a safe duo?. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14019

Vancouver

Koç Yıldırım S, Erbağcı E, Hapa A. Omalizumab treatment in combination with any other biologics: Is it really a safe duo?. Australasian Journal of Dermatology. 2023. doi:10.1111/ajd.14019

BibTeX
@article{KoYldrm2023,
  author = {Koç Yıldırım, Sema and Erbağcı, Ece and Hapa, Aslı},
  title = {Omalizumab treatment in combination with any other biologics: Is it really a safe duo?},
  journal = {Australasian Journal of Dermatology},
  year = {2023},
  doi = {10.1111/ajd.14019}
}
Kostenlos starten →